Key Development The Ministry of Health (MOH) of Vietnam issued Decision No. 2684/QD-BYT (signed by Vice Minister Nguyen Tri Thuc,... Read more
Category: Uncategorized
Macro Healthcare Economics & Pricing Controls: Vietnam Pharmaceutical and Healthcare CPI Expands 1.24% YoY Driven by Imported API and Logistics Costs – Ministry of Health Enforces Hospital Retail Margin Caps
Key Development According to the latest macroeconomic data released by the General Statistics Office (Ministry of Finance), the Consumer Price... Read more
Pharma Corporate Governance & Equity Realignment: Vidipha Chairman (HoSE: VDP) and Family Members Divest Entire ~30% Equity Stake on His 78th Birthday
Key Development According to official ownership disclosure filings submitted to the Ho Chi Minh City Stock Exchange (HoSE), Mr. Kieu... Read more
Healthcare Governance & Administrative Compliance: Ministry of Health Convenes Northern Regional Training on Citizen Reception, Dispute Resolution, and Anti-Corruption Oversight
Key Development In Thanh Hoa Province, the Ministry of Health (MOH) of Vietnam inaugurated its 2026 Professional Training Conference on... Read more
Accelerating National Healthcare Digital Transformation: Ministry of Health Expands Electronic Medical Records (EMR) Across 1,263 Hospitals and Integrates Over 34 Million Electronic Health Records on VNeID
Key Development On the afternoon of August 24, 2026, Assoc. Prof. Nguyen Tri Thuc, MD, PhD – Vice Minister of... Read more
Urban Primary Healthcare Reform: Ho Chi Minh City Department of Health Proposes 3-to-5-Year Secondment of Hospital Physicians as Community Health Station Directors to Anchor Multi-Tiered Healthcare Integration
Key Development On August 24, 2026, Assoc. Prof. Tang Chi Thuong, MD, PhD—Director of the Ho Chi Minh City Department... Read more
ASTRAZENECA VIETNAM’S LOGISTICS TRANSITION SIGNALS A BROADER PHARMA SHIFT
Key Development On August 22, 2026, Vietnam’s Ministry of Health issued Decision No. 2684/QĐ-BYT withdrawing AstraZeneca Vietnam’s pharmaceutical business eligibility... Read more
Biologics & ADC CDMO Consolidation: Piramal Pharma Acquires Controlling 74% Stake in Yapan Bio for $7.95 Million – Accelerating Integrated ADCelerate™ Bioconjugation Platform
Key Development Global biopharmaceutical enterprise Piramal Pharma Limited (PPL, NSE: PPLPHARMA / BSE: 543635) has formally completed the acquisition of... Read more
European CDMO Infrastructure Expansion: SK pharmteco Completes Major Manufacturing Expansions in Swords, Ireland – Boosting Small-Molecule API, High-Potency API (HPAPI), and ADC Payload Capabilities
Key Development Global contract development and manufacturing organization (CDMO) SK pharmteco (a subsidiary of South Korea's SK Group) has officially... Read more







